Physician profile
Daniel Eric Zainfeld
NPI 1972896777
$23,189.10
in general payments reported to CMS, 2019-2025
19 companies · $5,436 in 2025
The $5,436 reported for 2025 was more than what 91% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $104 · 2021: $188 · 2022: $1,117 · 2023: $6,041 · 2024: $9,649 · 2025: $5,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Education: $3,049 · Honoraria: $2,040 · Food and Beverage: $1,826 · Travel and Lodging: $1,680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,532.00 |
| Education | $3,048.64 |
| Honoraria | $2,040.00 |
| Food and Beverage | $1,826.28 |
| Travel and Lodging | $1,679.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $8,213.62 | 2021-2025 | Erleada |
| Intuitive Surgical, INC. | $5,513.68 | 2019-2025 | |
| Urogen Pharma, INC. | $2,838.96 | 2021-2025 | Jelmyto |
| Janssen Scientific Affairs, LLC | $1,988.64 | 2022-2023 | |
| Janssen Global Services, LLC | $1,691.89 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $1,640.06 | 2023-2025 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $840.00 | 2022 | |
| Astellas Pharma US INC | $106.36 | 2019-2024 | Veozah |
| Photocure INC | $85.10 | 2019 | |
| Merck Sharp & Dohme LLC | $72.97 | 2019-2023 | Keytruda, Lynparza |
| Ferring Pharmaceuticals INC. | $60.65 | 2024-2025 | Adstiladrin |
| Sumitomo Pharma America, INC. | $42.95 | 2024-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $31.19 | 2025 | |
| Olympus America INC. | $24.32 | 2025 | Uretero-Reno Fiberscope |
| Coloplast Corp | $14.98 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12.07 | 2025 | |
| Karl Storz Endoscopy-America | $11.66 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Zainfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.